Overview

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

Status:
Active, not recruiting

Trial end date:
2022-09-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacity and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.

Phase:

Phase 3

Details

Lead Sponsor:

Institut de Recherches Internationales Servier

Collaborator:

ADIR, a Servier Group company

Treatments:

Bumetanide